Publication:
A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer

Simple item page
dc.contributor.authorTOPÇU, Atakan
dc.contributor.authorYASİN, Ayşe İrem
dc.contributor.authorSHBAIR, ABDALLAH T.M.
dc.contributor.authorBEŞİROĞLU, MEHMET
dc.contributor.authorŞİMŞEK, MELİH
dc.contributor.authorSUCUOĞLU İŞLEYEN, ZEHRA
dc.contributor.authorYURTSEVER, İSMAİL
dc.contributor.authorGÜCİN, ZÜHAL
dc.contributor.authorŞEKER, Mesut
dc.contributor.authorTÜRK, HACI MEHMET
dc.contributor.institutionauthorTOPÇU, ATAKAN
dc.contributor.institutionauthorYASİN, AYŞE İREM
dc.contributor.institutionauthorSHBAIR, ABDALLAH T.M.
dc.contributor.institutionauthorBEŞİROĞLU, MEHMET
dc.contributor.institutionauthorŞİMŞEK, MELİH
dc.contributor.institutionauthorSUCUOĞLU İŞLEYEN, ZEHRA
dc.contributor.institutionauthorYURTSEVER, İSMAİL
dc.contributor.institutionauthorGÜCİN, ZÜHAL
dc.contributor.institutionauthorŞEKER, MESUT
dc.contributor.institutionauthorTÜRK, HACI MEHMET
dc.date.accessioned2021-07-06T20:59:11Z
dc.date.available2021-07-06T20:59:11Z
dc.date.issued2021-06-01T00:00:00Z
dc.description.abstractIntroduction Breast cancer is the most frequently diagnosed cancer in women worldwide. Ribociclib is now frequently used in the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer. Case Report A 54-year-old woman with breast cancer presented at a clinic in November 2017 with multiple lung and bone metastases. After receiving multiple lines of treatment due to disease progression, ribociclib and fulvestrant were initiated. Grade 4 toxicity was observed due to ribociclib during follow-up, and ribociclib was discontinued permanently. Management & Outcome: Given that liver transaminases and bilirubin elevation persisted despite discontinuation of the treatment, other reasons for liver toxicity were investigated. Abdominal MRI showed no liver metastases, although there was acute hepatitis. A liver biopsy was performed to determine the etiology. The pathology result was compatible with drug-induced acute fulminant toxic hepatitis. After liver biopsy, prednisolone treatment was initiated, after which the laboratory findings normalized. Discussion Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis.
dc.identifier.citationTOPÇU A., YASİN A. İ. , SHBAIR A. T. , BEŞİROĞLU M., ŞİMŞEK M., SUCUOĞLU İŞLEYEN Z., YURTSEVER İ., GÜCİN Z., ŞEKER M., TÜRK H. M. , -A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer-, JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021
dc.identifier.doi10.1177/10781552211027931
dc.identifier.pubmed34162247
dc.identifier.scopus85108833238
dc.identifier.urihttp://hdl.handle.net/20.500.12645/29026
dc.identifier.wosWOS:000666604700001
dc.titleA case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer
dc.typeArticle
dspace.entity.typePublication
local.avesis.idcb67e231-95c1-4201-9f3d-ccd9e626c9b0
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication37a739cd-75b5-4624-8d1e-a5d172edba69
relation.isAuthorOfPublicationdc78f073-a262-42b7-893f-38dcc921fdbb
relation.isAuthorOfPublicatione96c619d-48a1-488e-83ca-bff8d4cd7868
relation.isAuthorOfPublication362511ee-2781-4d17-af44-866a4b87b283
relation.isAuthorOfPublication037fbf0b-fefb-4173-9f93-478d96e2926f
relation.isAuthorOfPublicationdd5cc347-78e3-4a80-b807-67839aba11ed
relation.isAuthorOfPublication14d55114-49a3-4596-85af-789741e6b2f2
relation.isAuthorOfPublication874eeba5-cd5f-4437-9bdc-55caae8104f2
relation.isAuthorOfPublication8a03684e-e421-4a9f-9069-168fc121a5d4
relation.isAuthorOfPublication1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isAuthorOfPublication.latestForDiscovery14d55114-49a3-4596-85af-789741e6b2f2
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Collections
Yayınlar - Eserler